Market News

Cameco (Ccj) (CCJ) Holder Augustine Asset Management Trimmed Position by $550,287 as Share Price Declined; Intercept Pharmaceuticals In (ICPT) Shares Declined While Pacad Investment LTD Has Lowered by $822,498 Its Stake

Cameco Corporation (NYSE:CCJ) Logo

Augustine Asset Management Inc decreased its stake in Cameco Corp (Ccj) (CCJ) by 59.35% based on its latest 2017Q4 regulatory filing with the SEC. Augustine Asset Management Inc sold 61,143 shares as the company’s stock declined 3.93% with the market. The institutional investor held 41,878 shares of the precious metals company at the end of 2017Q4, valued at $386,000, down from 103,021 at the end of the previous reported quarter. Augustine Asset Management Inc who had been investing in Cameco Corp (Ccj) for a number of months, seems to be less bullish one the $3.94 billion market cap company. The stock decreased 2.08% or $0.22 during the last trading session, reaching $10.35. About 1.60M shares traded. Cameco Corporation (NYSE:CCJ) has declined 17.95% since April 23, 2017 and is downtrending. It has underperformed by 29.50% the S&P500.

Pacad Investment Ltd decreased its stake in Intercept Pharmaceuticals In (ICPT) by 85.53% based on its latest 2017Q4 regulatory filing with the SEC. Pacad Investment Ltd sold 14,181 shares as the company’s stock declined 3.60% with the market. The institutional investor held 2,400 shares of the health care company at the end of 2017Q4, valued at $140,000, down from 16,581 at the end of the previous reported quarter. Pacad Investment Ltd who had been investing in Intercept Pharmaceuticals In for a number of months, seems to be less bullish one the $2.04 billion market cap company. The stock increased 1.00% or $0.69 during the last trading session, reaching $69.42. About 86,875 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 48.35% since April 23, 2017 and is downtrending. It has underperformed by 59.90% the S&P500.

Analysts await Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report earnings on May, 3. They expect $-3.42 EPS, up 5.26% or $0.19 from last year’s $-3.61 per share. After $-4.43 actual EPS reported by Intercept Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -22.80% EPS growth.

Investors sentiment decreased to 1.31 in Q4 2017. Its down 0.02, from 1.33 in 2017Q3. It worsened, as 19 investors sold ICPT shares while 42 reduced holdings. 36 funds opened positions while 44 raised stakes. 17.97 million shares or 1.43% less from 18.23 million shares in 2017Q3 were reported. The California-based Capital Invsts has invested 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). British Columbia – Canada-based Pacad Invest Ltd has invested 0.03% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Rhenman And Asset Ab invested in 0.3% or 38,500 shares. Exane Derivatives holds 950 shares. Point72 Asia (Hong Kong) Ltd reported 304 shares. The Switzerland-based Swiss Savings Bank has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Pennsylvania-based Janney Montgomery Scott Ltd Liability Co has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Moreover, D E Shaw & Incorporated has 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 22,232 shares. Pinnacle invested 0.24% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Geode Cap Management Lc has 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Fmr Ltd Com has 0.03% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Balyasny Asset Mngmt Ltd Company has 50,716 shares. Point72 Asset Management Limited Partnership invested in 0.01% or 27,500 shares. State Street stated it has 1.25M shares. Connecticut-based Sarissa Capital Lp has invested 2.73% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Pacad Investment Ltd, which manages about $440.53M US Long portfolio, upped its stake in Verisign Inc (NASDAQ:VRSN) by 7,380 shares to 24,050 shares, valued at $2.75M in 2017Q4, according to the filing. It also increased its holding in Rollins Inc (NYSE:ROL) by 12,100 shares in the quarter, for a total of 16,100 shares, and has risen its stake in Tyson Foods Inc (NYSE:TSN).

Among 23 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 12 have Buy rating, 3 Sell and 8 Hold. Therefore 52% are positive. Intercept Pharmaceuticals had 74 analyst reports since August 10, 2015 according to SRatingsIntel. Wells Fargo maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) on Tuesday, February 13 with “Hold” rating. The rating was maintained by Cowen & Co with “Buy” on Monday, July 31. On Wednesday, October 4 the stock rating was downgraded by JMP Securities to “Market Perform”. Wedbush maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rating on Thursday, February 1. Wedbush has “Buy” rating and $253.0 target. BMO Capital Markets maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) on Thursday, February 15 with “Outperform” rating. The firm earned “Outperform” rating on Tuesday, April 17 by Wedbush. The rating was maintained by Cantor Fitzgerald with “Sell” on Tuesday, September 12. The firm has “Neutral” rating by Goldman Sachs given on Wednesday, March 30. The firm has “Sell” rating given on Friday, August 5 by Laidlaw. The rating was maintained by BMO Capital Markets on Friday, September 22 with “Outperform”.

Augustine Asset Management Inc, which manages about $270.82 million and $176.32 million US Long portfolio, upped its stake in Cabot Oil & Gas (Cog) (NYSE:COG) by 99,828 shares to 110,328 shares, valued at $3.16 million in 2017Q4, according to the filing. It also increased its holding in Taiwan Semiconductor (Tsm) (NYSE:TSM) by 12,039 shares in the quarter, for a total of 178,773 shares, and has risen its stake in Ecolab Inc (Ecl) (NYSE:ECL).

Analysts await Cameco Corporation (NYSE:CCJ) to report earnings on April, 27 before the open. They expect $-0.02 earnings per share, up 60.00% or $0.03 from last year’s $-0.05 per share. After $0.36 actual earnings per share reported by Cameco Corporation for the previous quarter, Wall Street now forecasts -105.56% negative EPS growth.

Among 6 analysts covering Cameco (NYSE:CCJ), 2 have Buy rating, 2 Sell and 2 Hold. Therefore 33% are positive. Cameco had 13 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Tuesday, February 14 by BMO Capital Markets. Bank of America downgraded Cameco Corporation (NYSE:CCJ) on Friday, June 30 to “Underperform” rating. Credit Suisse downgraded the stock to “Underperform” rating in Tuesday, July 18 report. The rating was maintained by RBC Capital Markets with “Outperform” on Tuesday, November 3. The stock has “Neutral” rating by Bank of America on Thursday, January 12. The rating was maintained by Bank of America with “Underperform” on Wednesday, October 4. RBC Capital Markets maintained it with “Buy” rating and $16.0 target in Friday, October 20 report. The firm has “Sector Perform” rating given on Thursday, April 7 by Scotia Capital. The rating was downgraded by Bank of America to “Neutral” on Thursday, July 21. The firm has “Market Perform” rating given on Thursday, August 6 by Cowen & Co.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *